证券代码：603014 证券简称：威高血净 公告编号：2026-009 山东威高血液净化制品股份有限公司 关于发行股份购买资产暨关联交易相关内幕信息知情人 买卖股票情况自查报告的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东威高血液净化制品股份有限公司（以下简称"威高血净"、"公司"或"上 市公司"）拟通过发行股份方式购买山东威高普瑞医药包装有限公司 100%股权（以 下简称"本次交易"或"本次重组"）。根据《中华人民共和国证券法》《上市公 司重大资产重组管理办法》《上市公司监管指引第 7 号——上市公司重大资产重组 相关股票异常交易监管》《公开发行证券的公司信息披露内容与格式准则第 26 号 ——上市公司重大资产重组》《监管规则适用指引——上市类第 1 号》等法律、法 规的要求，公司对本次交易相关内幕信息知情人买卖股票情况进行了自查，本次自 查的具体情况如下： 一、本次交易内幕信息知情人自查期间 本次交易内幕信息知情人关于买卖上市公司股票情况的自查期间为上市公司就 本次交易事项首次停牌前六个月至上市公司重组报告书 ...

Core Viewpoint - The company plans to issue shares to acquire 100% equity of Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd, with a self-inspection period from May 19, 2025, to January 5, 2026 [1] Group 1 - The self-inspection covers the listed company, transaction parties, and related personnel [1] - During the self-inspection, it was found that the company's securities affairs department staff's immediate relative, Xu Chengling, bought and sold 1,400 shares, while the controlling shareholder's director, Zhao Chunxu, bought and sold 7,500 shares [1] - Both individuals claimed not to have used insider information for trading and committed to not trading before the completion of the restructuring [1] Group 2 - The self-inspection and intermediary institution's verification concluded that the trading activities of the relevant parties did not constitute insider trading and do not affect the restructuring [1]

山东威高血液净化制品股份有限公司 2026年第一次临时股东会 会议资料 证券代码:603014 2026年2月 0 | 2026年第一次临时股东会会议须知 | 3 | | --- | --- | | 2026年第一次临时股东会议程 4 | | | 议案一 6 | | | 关于公司发行股份购买资产暨关联交易符合相关法律法规的议案 6 | | | 议案二 7 | | | 关于公司发行股份购买资产暨关联交易方案的议案 7 | | | 议案三 12 | | | 其摘要的议案 12 | | | 议案四 13 | | | 关于本次交易构成关联交易的议案 | 13 | | 议案五 14 | | | 关于本次交易构成重大资产重组但不构成重组上市的议案 | 14 | | 议案六 15 | | | 第四条规定的议案 | 15 | | 议案七 16 | | | 定的议案 16 | | | 议案八 18 | | | 三十条情形的议案 18 | | | 议案九 19 | | | 关于签署附条件生效的《发行股份购买资产协议》的议案 19 | | | 议案十 20 | | | 关于签署附条件生效的《发行股份购买资产协议之补充协议》《盈利预 ...

Group 1 - The core viewpoint of the news is that Weigao Blood Purification has shown a slight decline in stock price and trading volume, with notable financing activities indicating investor behavior [1] - As of February 12, Weigao Blood Purification's financing balance is 116 million yuan, accounting for 7.24% of its market capitalization [1] - The company reported a total revenue of 2.736 billion yuan for the period from January to September 2025, reflecting a year-on-year growth of 3.45% [2] Group 2 - The net profit attributable to the parent company for the same period was 341 million yuan, representing a year-on-year increase of 7.92% [2] - The company has distributed a total of 65.8213 million yuan in dividends since its A-share listing [3] - As of September 30, the number of shareholders decreased by 20.95% to 24,800, while the average circulating shares per person increased by 26.51% to 1,535 shares [2]

Core Viewpoint - The company, Shandong Weigao Blood Purification Products Co., Ltd., has announced the convening of its first extraordinary general meeting of shareholders in 2026, scheduled for February 27, 2026 [2]. Meeting Details - The meeting will be held on February 27, 2026, at 3:00 PM at the Weigao Blood Purification Office Building, Room 601, Weigao West Road 7, Weihai, Shandong Province [5]. - Shareholders can participate through both on-site voting and an online voting system provided by the Shanghai Stock Exchange [5][6]. - The online voting will be available from 9:15 AM to 3:00 PM on the day of the meeting [3]. Voting Procedures - Shareholders must register to attend the meeting by providing necessary documentation, including proof of shareholding and identification [12]. - The voting process allows for multiple accounts to be used, but only the first vote will be counted if there are duplicate votes [8]. - Specific procedures are outlined for shareholders involved in margin trading, transfer, and other related accounts [4]. Agenda and Resolutions - The meeting will review and vote on 21 special resolutions, with provisions for separate counting of votes from minority investors [7]. - Certain related shareholders are required to abstain from voting on specific resolutions [7]. Additional Information - The meeting is expected to last half a day, and attendees are responsible for their own expenses [13]. - Contact information for inquiries regarding the meeting is provided, including a contact person and phone number [13].

一、召开会议的基本情况 （一）股东会类型和届次 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603014 证券简称：威高血净 公告编号：2026-008 山东威高血液净化制品股份有限公司 关于召开2026年第一次临时股东会的通知 2026年第一次临时股东会 （二）股东会召集人：董事会 （三）投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结 合的方式 （四）现场会议召开的日期、时间和地点 召开地点：山东省威海市威高西路 7 号威高血液净化办公楼 6 楼 601 会议室 （五）网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 2 月 27 日至2026 年 2 月 27 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东会召开当日的 9:15-15:00。 （六）融资融 ...

Group 1 - The core viewpoint of the news is that Weigao Blood Purification has shown a slight increase in stock price and has reported its financial performance, indicating growth in revenue and net profit [1][2]. - As of February 9, Weigao Blood Purification's stock price increased by 0.47%, with a trading volume of 36.10 million yuan. The financing buy-in amount was 5.05 million yuan, while the financing repayment was 7.37 million yuan, resulting in a net financing buy of -2.32 million yuan [1]. - The total balance of margin trading for Weigao Blood Purification as of February 9 is 120 million yuan, which accounts for 7.56% of its circulating market value [1]. Group 2 - As of September 30, the number of shareholders for Weigao Blood Purification is 24,800, a decrease of 20.95% from the previous period. The average circulating shares per person increased by 26.51% to 1,535 shares [2]. - For the period from January to September 2025, Weigao Blood Purification achieved an operating income of 2.736 billion yuan, representing a year-on-year growth of 3.45%. The net profit attributable to the parent company was 341 million yuan, with a year-on-year increase of 7.92% [2]. - Since its A-share listing, Weigao Blood Purification has distributed a total of 65.82 million yuan in dividends [3].

Group 1 - The core viewpoint of the news is that Weigao Blood Purification has shown a slight decline in stock price while maintaining a stable financing balance and positive revenue growth [1][2]. - As of February 6, Weigao Blood Purification's stock price decreased by 0.69%, with a trading volume of 33.35 million yuan. The net financing purchase on that day was 1.54 million yuan, with a total financing and securities balance of 123 million yuan [1]. - The company reported a revenue of 2.736 billion yuan for the period from January to September 2025, reflecting a year-on-year growth of 3.45%, and a net profit attributable to shareholders of 341 million yuan, which is a 7.92% increase year-on-year [2]. Group 2 - The company has a significant portion of its revenue coming from consumables, accounting for 77.55%, while equipment contributes 18.25%, and other sources make up 2.35% and 1.85% respectively [1]. - As of September 30, the number of shareholders for Weigao Blood Purification was 24,800, a decrease of 20.95% from the previous period, while the average circulating shares per person increased by 26.51% to 1,535 shares [2]. - Since its A-share listing, Weigao Blood Purification has distributed a total of 65.82 million yuan in dividends [3].

Core Viewpoint - The company has successfully redeemed structured deposit products amounting to 235 million RMB, generating a total return of 364,300 RMB from these investments [1][2]. Group 1: Redemption Details - The total redemption amount for the structured deposit products is 235 million RMB [1]. - The structured deposit products were purchased from Weihai Bank and Minsheng Bank, with amounts of 180 million RMB and 55 million RMB respectively [1]. - The total return from the redeemed products is 364,300 RMB [2]. Group 2: Cash Management Status - As of the announcement date, the company has a remaining balance of 240 million RMB in unused raised funds for cash management, which is within the authorized limits set by the board [2]. - The company is authorized to use up to 740 million RMB of temporarily idle raised funds for cash management, ensuring that it does not affect the construction and use of the raised funds [1].

证券代码：603014 证券简称：威高血净 公告编号：2026-007 山东威高血液净化制品股份有限公司 关于使用暂时闲置募集资金进行现金管理 到期赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 二、截至本公告日，授权有效期内使用募集资金进行现金管理的情况 截至本公告披露日，公司使用闲置募集资金进行现金管理未到期余额为 24,000.00 万元人民币，未超过董事会授权使用闲置募集资金进行现金管理的金额范 围和投资期限。 单位：万元 | 序 | 购买 | 签约银行 | 产品名 | 认购金额 | 起息日 | 到期日 | 预期年化收益率 | 赎回金额 | 实际收 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | 主体 | | 称 | | | | | | 益 | | 1 | 威高 血净 | 威海银行股 份有限公司 东城支行 | 结构性 存款 | 18,000.00 | 2026/1/1 | 2026/1/31 | 0. ...